Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer

SIMPLE SUMMARY: Most patients with advanced non-small cell lung cancer (NSCLC) do not respond to programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis blockade, highlighting the need for the identification of new targets for immune checkpoint inhibition. In this study, we use...

Descripción completa

Detalles Bibliográficos
Autores principales: Vathiotis, Ioannis A., MacNeil, Tyler, Zugazagoitia, Jon, Syrigos, Konstantinos N., Aung, Thazin Nwe, Gruver, Aaron M., Vaillancourt, Peter, Hughes, Ina, Hinton, Steve, Driscoll, Kyla, Rimm, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957629/
https://www.ncbi.nlm.nih.gov/pubmed/33804482
http://dx.doi.org/10.3390/cancers13051024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957629/
https://www.ncbi.nlm.nih.gov/pubmed/33804482
http://dx.doi.org/10.3390/cancers13051024

Ejemplares similares